Arvinas (NASDAQ:ARVN) Receives “Overweight” Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Arvinas (NASDAQ:ARVN) in a report released on Wednesday,Benzinga reports. They currently have a $20.00 price target on the stock, up from their previous price target of $16.00.

A number of other analysts have also recently commented on ARVN. Barclays upped their target price on shares of Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Stephens boosted their price objective on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and raised their target price for the stock from $10.00 to $15.00 in a report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded Arvinas from a “sell” rating to a “hold” rating in a research report on Sunday. Ten investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $13.47.

Arvinas Stock Performance

ARVN stock opened at $13.30 on Wednesday. The company has a market cap of $854.13 million, a price-to-earnings ratio of -10.39 and a beta of 1.88. The business’s 50-day moving average is $12.40 and its two-hundred day moving average is $10.53. Arvinas has a fifty-two week low of $5.90 and a fifty-two week high of $18.93.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative net margin of 30.77% and a negative return on equity of 13.22%. The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. The company’s revenue for the quarter was down 84.0% compared to the same quarter last year. Equities analysts predict that Arvinas will post -3.81 earnings per share for the current year.

Insider Transactions at Arvinas

In related news, CFO Andrew Saik sold 5,134 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the sale, the chief financial officer owned 159,267 shares in the company, valued at approximately $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Randy Teel sold 4,786 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the completion of the transaction, the chief executive officer directly owned 149,696 shares in the company, valued at approximately $1,820,303.36. This represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,132 shares of company stock valued at $264,741 over the last 90 days. Company insiders own 4.73% of the company’s stock.

Hedge Funds Weigh In On Arvinas

Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC increased its holdings in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after purchasing an additional 3,500 shares during the last quarter. State of Wyoming purchased a new stake in shares of Arvinas in the third quarter worth about $68,000. Abel Hall LLC purchased a new stake in shares of Arvinas in the fourth quarter worth about $125,000. Finally, Corient Private Wealth LLC bought a new position in Arvinas during the fourth quarter valued at approximately $127,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Key Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reaffirmed an “overweight” rating and raised its price target to $20 (from $16), boosting upside expectations for the stock. Piper Sandler price target raise
• Positive Sentiment: Company update highlights multiple 2026 clinical data milestones (ARV-102, ARV-806, ARV-393 and others) and states a cash runway into the second half of 2028 — a clear de-risking signal for development-stage investors. Corporate update and cash runway
• Positive Sentiment: Market coverage highlighted Arvinas’s promising pipeline and favorable forward-looking sentiment in futures trading, adding short-term momentum. Kalkine: promising pipeline
• Neutral Sentiment: Consensus analyst stance remains mixed — the stock carries an average “Hold” rating from the broader analyst community, tempering uniform bullishness. Analyst consensus: Hold
• Neutral Sentiment: Reported short-interest data appears anomalous/zero in the latest release and is not a meaningful current driver. (Data flagged as effectively 0 days to cover.)
• Negative Sentiment: Q4 results disappointed: EPS of ($1.10) missed consensus (~($0.55)) and revenue fell sharply to $9.5M vs. estimates near $37M — a material near-term negative with implications for near-term guidance and sentiment. Zacks: Q4 loss and revenue miss
• Negative Sentiment: CEO Randy Teel sold 4,786 shares on Feb 23 (filed Form 4), trimming his stake — an insider sale that some investors view as a short-term negative signal. SEC Form 4: CEO sale
• Negative Sentiment: CAO David Loomis also sold 1,108 shares on Feb 23, a smaller insider sale that further contributes to negative optics. SEC Form 4: CAO sale

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.